Key clinical trials of remdesivir in COVID-19

Drug(s)	Phase	Status	Location(s)	Identifier	Sponsor (Collaborator)
Remdesivir	II/III	Recruiting	Multinational	NCT04431453 (CARAVAN)	Gilead Sciences
Remdesivir, placebo	III	Terminated	China	NCT04257656	Capital Medical University
Remdesivir, SOC	III	Completed	Multinational	NCT04292730 (SIMPLE-moderate)	Gilead Sciences
Remdesivir, SOC	III	Completed	Multinational	NCT04292899 (SIMPLE-severe)	Gilead Sciences
Remdesivir, placebo	III	Completed	Multinational	NCT04280705 (ACTT-1)	NIAID
Remdesivir, baricitinib, placebo	III	Active	Multinational	NCT04401579 (ACTT-2)	NIAID
Remdesivir, tocilizumab, placebo	III	Recruiting	Multinational	NCT04409262 (REMDACTA)	Hoffmann-La Roche (Gilead Sciences)

NIAID National Institute of Allergy and Infectious Diseases, SOC standard of care